New eczema cream tested for safety in kids

NCT ID NCT05186805

Summary

This study tested the safety and how much of a new topical cream called tapinarof gets into the body when used by children with widespread atopic dermatitis (eczema). 36 children aged 2 to 17 applied the cream daily for 4 weeks. The main goal was to check for side effects and measure the drug levels in the blood, while also seeing if the eczema improved.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dermavant Investigative Site

    Thousand Oaks, California, 91320, United States

  • Dermavant Investigative Site

    Centennial, Colorado, 80112, United States

  • Dermavant Investigative Site

    Coral Gables, Florida, 33146, United States

  • Dermavant Investigative Site

    Hialeah, Florida, 33016, United States

  • Dermavant Investigative Site

    Miami Lakes, Florida, 33014, United States

  • Dermavant Investigative Site

    Chicago, Illinois, 60611, United States

  • Dermavant Investigative Site

    Summerville, South Carolina, 29445, United States

  • Dermavant Investigative Site

    Houston, Texas, 77030, United States

  • Dermavant Investigative Site

    San Antonio, Texas, 78213, United States

  • Dermavant Investigative Site

    Calgary, Alberta, T3A 2N1, Canada

Conditions

Explore the condition pages connected to this study.